Procurement loss and profit dip offset aesthetics and FDA wins
Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.
This is the biggest negative force this period, directly threatening a large chunk of revenue.
Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.
New product approvals are a positive growth driver that can lift investor sentiment.
FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.
A regulatory win for a novel cancer drug adds credibility and future revenue potential.
Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.
The earnings report is the key financial update, showing both stability and a concerning quarterly decline.